Table 1

Details of studies included in the review

Bainey et al18Rosenstock et al17Wolak et al16Coca et al19Goksuluk et al21*Weisbord et al20
Study designRCTRCTRCTProspective cohortProspective cohortProspective cohort
Sample size2082209410178044
CountryCanadaUSAIsraelNorth AmericaTurkeyUSA
PopulationCoronary angiographyCoronary angiographyCoronary angiographyCardiac surgeryCoronary angiographyCoronary angiography
Risk groupCKDCKDNoneHigh risk of AKIDiabetesCKD
Mean age (SD)Intervention: 73 (9)
Control: 72 (8)
Intervention: 72(10) Control: 72 (10)65 (12)Intervention: 71(11)
Control: 70 (12)
NRNR
Female (%)26523331NRNR
AKI definitionIncrease in SCr ≥25% or ≥0.5 mg from baselineIncrease in SCr >25% or 0.5 mg from baselineIncrease in SCr ≥25% from baselineIncrease in SCr ≥50% or ≥0.3 mg from baselineIncrease in SCr ≥25% or ≥0.5 mg from baselineIncrease in SCr ≥25% from baseline or ≥0.5 mg from baseline
ComorbiditiesDiabetes (54%), hypertension (47%), congestive heart failure (14%), liver cirrhosis (1%)Hypotension (97%), diabetes (55%)Diabetes (50%), unstable angina (62%)Diabetes (47%), Hypertension (88%), congestive heart failure (23%)Diabetes (100%)NR
Study drugACE/ARBACE/ARBACE/ARBACE/ARBACE/ARBNSAIDs
Intervention: timing of hold24 hours prior to procedureDay of procedure24 hours prior to procedureMorning of surgery24 hours before procedureNo details
Intervention: timing of restartUp to 96 hours postprocedure24 hours postprocedure(1) Immediately afterwards; (2) 24 hours afterNo detailsNo detailsNo details
ControlContinued throughout studyContinued throughout studyContinued throughout studyContinued throughout studyContinued throughout studyContinued throughout study
Risk of biasLowSome: randomised by coin toss, no information on allocation concealment. Baseline difference compatible with chanceSome; no information on treatment allocation, baseline difference compatible with chanceModerate; controlled for confounding but possibility of residual confoundingCritical; no control for confoundingNot assessed
  • *Available only as conference abstract.

  • ACE, angiotensin-converting enzyme inhibitors; AKI, acute kidney infection; ARB, angiotensin receptor blockers; CKD, chronic kidney disease; NSAIDs, non-steroidal anti-inflammatory drugs; RCT, randomised controlled trial; SCr, serum creatinine.